Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfatinib with Etoposide and Ifosfamide in Relapsed or Refractory Osteosarcoma
NCT05590572Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of surufatinib in osteosarcoma (OS), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT05590572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590572.